


Abstract 2022-LBA-414-ESGO Table 1 Adverse event (AE) summary

| Preferred term | Serious AEs in $\geq 5\%$ of patients overall, N=44 | Serious AEs related to T-cell infusion in $\geq 5\%$ of patients overall, N=44 | Serious AEs in patients with ovarian cancer, N=14 | Serious AEs related to T-cell infusion in patients with ovarian cancer, N=14 |
|--|---|--|---|--|
| Any serious AE, n (%) | 27 (61.4) | 21 (47.7) | 11 (78.6) | 10 (71.4) |
| Cytokine release syndrome (CRS) | 14 (31.8) | 14 (31.8) | 7 (50.0) | 7 (50.0) |
| | | | [including 1 grade 5 event in a 60-year-old with large tumor burden in lungs and previous lung radiotherapy. Cause of death: pneumonia and CRS] | |
| Hypoxia | 3 (6.8) | 3 (6.8) | 3 (21.4) | 3 (21.4) |
| Immune effector cell-associated neurotoxicity syndrome | 3 (6.8) | 3 (6.8) | 1 (7.1) | 1 (7.1) |
| Pyrexia | 3 (6.8) | 2 (4.5) | 2 (14.3) | 2 (14.3) |
| Preferred term | AEs related to T-cell infusion in $\geq 12\%$ of patients overall, N=44 | AEs related to T-cell infusion in patients with ovarian cancer, N=14 | | |
| Any AE | 40 (90.9) | 14 (100.0) | | |
| Cytokine release syndrome | 32 (72.7) | 11 (78.6) | | |
| Neutropenia/neutrophil count decreased | 13 (29.5) | 4 (28.6) | | |
| Anemia/RBC decreased | 10 (22.7) | 3 (21.4) | | |
| Pyrexia | 10 (22.7) | 5 (35.7) | | |
| Fatigue | 9 (20.5) | 4 (28.6) | | |
| Leukopenia/WBC decreased | 7 (15.9) | 2 (14.3) | | |
| Rash | 7 (15.9) | 3 (21.4) | | |
| Thrombocytopenia/platelet count decreased | 7 (15.9) | 2 (14.3) | | |
| Dyspnoea | 6 (13.6) | 3 (21.4) | | |
| Hypoxia | 6 (13.6) | 3 (21.4) | | |
| Immune effector cell-associated neurotoxicity syndrome | 6 (13.6) | 1 (7.1) | | |
| Pleural effusion | 6 (13.6) | 1 (7.1) | | |

**Abstract 2022-LBA-414-ESGO Figure 1**

Conclusions ADP-A2M4CD8 SPEAR T-cell therapy showed preliminary anti-tumour activity in heavily pre-treated patients with MAGE-A4+ advanced ovarian cancer, with tolerable emerging safety results. The trial now includes an anti-programmed death-ligand 1 combination treatment cohort. 1. Hong DS, et al. *Ann Oncol.* 2021;32(suppl5):540P.

2022-LBA-677-ESGO DISTRIBUTION AND PROGNOSTIC ROLE OF BRCA STATUS IN ELDERLY OVARIAN CANCER PATIENTS

¹Lucia Tortorella, ¹Serena Cappuccio, ¹Claudia Marchetti, ¹Barbara Costantini, ¹Diana Giannarelli, ²Giuseppe Vizzielli, ¹Tina Pasciuto, ³Domenica Lorusso, ³Giovanni Scambia, ³Anna Fagotti. ¹Fondazione Policlinico Gemelli IRCCS, Roma, Italy; ²University Hospital of Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; ³Fondazione Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore., Roma, Italy

10.1136/ijgc-2022-ESGO.1020

Introduction Elderly patients with advanced ovarian cancer often receive suboptimal treatment with less radical surgery, due to the complexity and risks of primary debulking surgery (PDS). We know that complete resection is the most important independent factor affecting survival. There is an emerging role of BRCA status. BRCA mut patients are more chemosensitive while BRCA wt could better benefit of PDS. In this context it's important to evaluate the distribution of BRCA status in elderly patients and if its prognostic role is still maintained in this subgroup of patients.


Methods This is a retrospective single institution study evaluating patients with known germinal/somatic BRCA status. We are comparing clinical and surgical characteristics according to age groups. We are evaluating the prevalence of BRCA mut in the age groups, how it affects survival and chemosensitivity in order to understand if in elderly patients its prognostic role is still maintained

Results A total of 2089 patients were included in the analysis. Mean age of BRCAmut was 55.8 (SD=10.9) and 60.3 (SD=12) for BRCAwt ($p < 0.0001$). The rate of BRCAmut decreases over age-range (figure 1). 1850 patients were stage IIIC-IV and older women were less likely submitted to PDS (from 62.1% for < 50 y to 23.4% for ≥ 80 y), however the rate of complete resection was superimposable in all age

range. Median Progression Free Survival (PFS) in women >65 y for PDS and IDS was respectively 29.7 vs 23.4 months ($p=0.66$) for BRCAmut, and 21.0 vs 15.4 months ($p=0.004$) for BRCAwt.

Abstract 2022-LBA-677-ESGO Table 1 Distribution of BRCA status according to age

| Age group | BRCA wt | BRCA mut | Total |
|---------------|---------------------|--------------------|-------------|
| <50 | 243 (50.0%) | 243 (50.0%) | 486 |
| 50-59 | 356 (58.4%) | 254 (41.6%) | 610 |
| 60-69 | 387 (67.4%) | 187 (32.6%) | 574 |
| 70-79 | 277 (78.2%) | 77 (21.8%) | 354 |
| >=80 | 51 (78.5%) | 14 (21.5%) | 65 |
| Totale | 1314 (62.9%) | 775 (37.1%) | 2089 |



Abstract 2022-LBA-677-ESGO Figure 1 Kalpan-Meyer plots for progression free survival in (A) BRCAwt and (B) BRCA2mut in the older population (>65 years)

Conclusions BRCAmut is often associated to younger age, reaching the 50% in patients <50 y, however the rate of mutation in older age is not trascurable. BRCAmut patients maintain the best prognosis even in the older group. BRCAwt are less likely to respond to chemotherapy and in this group upfront surgery with complete resection makes the difference.

2022-LBA-714-ESGO FULL-THICKNESS PARTIAL DIAPHRAGM RESECTION USING AN ENDO GIA VASCULAR STAPLER IN PATIENTS WITH ADVANCED-STAGE OVARIAN CANCER: AN INSTITUTIONAL SERIES

^{1,2}Daniela Huber, ³Ian Fournier, ⁴James Nef, ⁵Michel Christodoulou, ¹Stéphanie Seidler, ⁶Valérie Besse, ²Yannick Hurni. ¹Obstetrics and Gynecology, Valais Hospital, Sion, Switzerland; ²Pediatrics, Obstetrics and Gynecology, Geneva University Hospital, Geneva, Switzerland; ³General Surgery, Valais Hospital, Sion, Switzerland; ⁴UNIGE, Geneva, Switzerland; ⁵Thoracic Surgery, Valais Hospital, Sion, Switzerland; ⁶Radiology, Valais Hospital, Sion, Switzerland

10.1136/ijgc-2022-ESGO.1021

Introduction Patients with advanced-stage ovarian cancer frequently present with peritoneal carcinomatosis with a diaphragmatic involvement. During cytoreduction surgeries, deep infiltrating nodules require diaphragmatic full-thickness resections (DFTRs). These procedures involve opening the pleural cavity, often requiring a chest drain, and are associated with a high rate of postoperative complications. We present a novel technique to perform DFTRs using a surgical stapler without opening the pleural cavity, and we report our preliminary results.

Methods Analysis of consecutive patients undergoing full thickness diaphragmatic resection using an EndoGIA vascular stapler by a single surgical team since January 2018.

Results Fifteen patients underwent cytoreductive surgeries with S-DFTRs. The median operative time was 300 (114 – 547) minutes. Cytoreduction was considered complete in all cases. Concomitant contralateral diaphragmatic peritoneal stripping was performed in 5 cases (33.3%) and was associated with a conventional DFTR in 1 case (6.7%). Pleural effusion was observed in 9 patients (60.0%), and 4 (26.7%) required a postoperative pigtail catheter thoracostomy. Three patients (20.0%) required catheter placement (ipsilaterally to the S-DFTR) and 2 patients (13.3%) required catheters on the contralateral hemithorax. Pulmonary embolism and pneumonia were both observed once (6.7%). The median hospitalization length was 14 (5 – 36) days. During the follow-up, 6 patients (40.0%) had a recurrence, but none involved the pleura or the diaphragm.

Conclusions This technique appears as a safe and easy method for performing diaphragmatic resections and could reduce postoperative complications.

2022-LBA-750-ESGO RECTAL CANCER VERSUS ENDOMETRIOSIS ON ULTRASOUND IN METASTATIC OVARY

Ahmed Elagwany. Alex uni, Alexandria, Egypt

10.1136/ijgc-2022-ESGO.1022

Introduction Ultrasound is now available everywhere with high advancement in technology. There are some findings on ultrasound that can be very similar on appearance. These include the rectal endometriosis and rectal cancer especially if there is adnexal masses associated.

Methods we are aiming here to show the difference and illustrate the findings for differentiation through presentation of 2 different cases.

Results IOTA scoring system is very important in initial assessment of masses, and it can be memorized easily. And after its application, expert ultrasound can help with pattern recognition of masses. Rectal cancer and rectal endometriosis can be easily mistaken or even can be missed so we aimed here to clarify them through discussion od 2 cases. Furthermore, mucin cancer typical appearance was not reported before on literature regarding the typical intestinal mucinous cystadenocarcinoma of the ovary and metastatic ovary with vessels sign also are shown here in a typical appearance.

Conclusions finally we aimed to show some ultrasound findings that was previously can be seen on ultrasound, now with advancement in technology, we can so that even better than the MRI and CT especially in the pelvic region.

2022-LBA-751-ESGO NODAL VERSUS PERITONEAL METASTASIS ON ULTRASOUND

Ahmed Elagwany. Alex uni, Alexandria, Egypt

10.1136/ijgc-2022-ESGO.1023

Introduction Granulosa cell tumors are rare ovarian neoplasms and they can metastasize and recur. Due to its rarity, limited data are available on nodal metastasis and recurrence. Recurrence after staging surgery can be nodal or peritoneal related to the lateral pelvic wall.